title: Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.
abstract: Four patients with the hemolytic uremic syndrome secondary to mitomycin therapy were treated with intense plasmapheresis and antiplatelet agents. All four patients had a hematologic response and three had slow, but steady, improvement in renal function. These results suggest an important role for these agents in mitomycin-induced hemolytic uremic syndrome.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives*; D001125:Argininosuccinic Acid / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D003404:Creatinine / Q000097:blood; D004176:Dipyridamole / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects*; D010956:Plasmapheresis; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D013608:Tablets, Enteric-Coated; D013997:Time Factors
chemical_list: D008937:Mitomycins; D013608:Tablets, Enteric-Coated; D001125:Argininosuccinic Acid; D016685:Mitomycin; D004176:Dipyridamole; D001120:Arginine; D003404:Creatinine; D013442:Sulfinpyrazone